This study aimed to optimize a reliable and rapid genotyping assay to detect the carriers of bovine citrullinemia (BC), bovine leukocyte adhesion deficiency (BLAD), complex vertebral malformation (CVM), and deficiency of uridine monophosphate synthase (DUMPS) in cattle populations. We developed real-time polymerase chain reaction (RT-PCR)-based assays to distinguish wild-type and defective alleles of BLAD, CVM, BC, and DUMPS. Twenty-four bulls in the International Center for Livestock Research and Training were genotyped. At the same time, genotyping was performed for [...] ABSTRACT This study aimed to optimize a reliable and rapid genotyping assay to detect the carriers of bovine citrullinemia (BC), bovine leukocyte adhesion deficiency (BLAD), complex vertebral malformation (CVM), and deficiency of uridine monophosphate synthase (DUMPS) in cattle populations. We developed real-time polymerase chain reaction (RT-PCR)-based assays to distinguish wild-type and defective alleles of BLAD, CVM, BC, and DUMPS. Twenty-four bulls in the International Center for Livestock Research and Training were genotyped. At the same time, genotyping was performed for

Background/aim: Our recent study revealed that the expression of lipoxygenase (LOX) and cyclooxygenase (COX) enzymes in the hypothalamus is activated by nesfatin-1, leading to the liberation of leukotrienes and prostaglandins (PG), respectively. Moreover, our prior report explained that intracerebroventricular (ICV) nesfatin-1 treatment triggers cardiovascular responses mediated by central LOX and COX enzymes. Building upon our prior reports, the present investigation sought to clarify the role of cardiovascularly active central COX products, such as thromboxane (TX) A2, PGF2α, PGE, and PGD, in orchestrating nesfatin-1-evoked reactions in mean arterial pressure (MAP) and heart rate (HR).Materials and methods: The Sprague Dawley rats, which had guide cannula in the lateral ventricle for intracerebroventricular (ICV) injections and catheter in arteria femoralis for monitoring MAP and HR, were underwent central pretreatment with furegrelate (the TXA2 synthase inhibitor), PGF2α-dimethylamine (PGF2α-DA, the PGF2α receptor antagonist), or AH6809 (the PGE and PGD receptor antagonist), 5 min prior to ICV nesfatin-1 administration. The cardiovascular parameters were observed and recorded for 60 min posttreatmentResults: Nesfatin-1 induced cardiovascular responses in rats leading to pressor effect in MAP, and tachycardia following bradycardia in HR. Interestingly, ICV furegrelate, PGF2α-DA, or AH6809 pretreatment partially mitigated the cardiovascular effects revealed by nesfatin-1.Conclusion: The findings illuminate the role of nesfatin-1 in modulating MAP and HR through the central activation of specifically TXA2, PGF2α, PGE, and PGD from COX metabolites. Additionally, the study may also suggest the potential involvement of other central COX or LOX metabolites beyond these COX metabolites in mediating the cardiovascular effects produced by nesfatin-1.

Nesfatin-1 has a role in appetite control and energy balance. The activity of the cholinergic system also is able to affect feeding behavior. Moreover, the central cholinergic system interacts with central nesfatinergic systems. The main goal of the study was to determine the effect of intracerebroventricular (icv) and intravenous (iv) administrated CDP-choline (0.5 ve 1 μmol; icv ve 250 mg / kg; iv) on levels of plasma nesfatin-1 in the homogeneous number of male and female fasted and the satiated Wistar albino rats. The polyethylene cannula was inserted into the carotid artery and jugular vein of the rats anesthetized with sevoflurane (2–4%/100% O2) to collect blood samples and to make iv injection, respectively. For icv treatment, the lateral ventricle of rats was cannulated with guide cannula. The basal levels of plasma nesfatin-1 in the satiated rats were higher than those observed in the fasted animals. While 0.5 and 1 μmol dose of icv and/or 250 mg/kg dose of iv injected CDP-choline increased the level of plasma nesfatin-1 in the satiated rats, plasma nesfatin-1 level of the fasted animals decreased after the same dose and route of CDP-choline injection. The current findings show that CDP-choline can influence the level of plasma nesfatin-1 in the rats. The effect of the drug was different according to the food intake of the rats. These data might suggest a potential role in CDP-choline on plasma nesfatin-1 concentration.

Neutering of dogs, whether male or female, provides various benefits such as contraception, population control, and the prevention of reproductive disorders and undesirable sexual behaviors. However, it is also associated with an increased risk of obesity, which may be directly linked to post-neutering hormonal changes. Our study aims to determine the effects of neutering on plasma levels of nesfatin-1, serotonin, dopamine, TSH, and T4—hormones implicated in obesity and metabolic regulation. Fourteen dogs (seven males and seven females), aged between 1 and 3 years, were included in this study. Male dogs underwent orchiectomy and females underwent ovariohysterectomy. Blood samples were collected before surgery and on days 7 and 14 post-operatively to measure the plasma levels of these hormones using ELISA. The results showed a significant decrease in nesfatin-1, serotonin, and T4 levels, along with a significant increase in TSH levels in both male and female dogs post-neutering. While these hormonal changes are likely part of the body’s adaptive response to neutering, they may represent a potential mechanism that contributes to the long-term tendency toward obesity in neutered dogs.